A phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in the intensification of cisplatin and cyclophosphamide chemotherapy for advanced ovarian cancer. by Kehoe, S. et al.
Br. J. Cancer (1994), 69, 537-540 Macmillan Press
A phase I/II trial of recombinant human granulocyte-macrophage
colony-stimulating factor in the intensification of cisplatin and
cyclophosphamide chemotherapy for advanced ovarian cancer
S. Kehoe, C.J. Poole, A. Stanley, H.M. Earl & G.R.P. Blackledge
Cancer Research Campaign Trials Unit, Queen Elizabeth Medical Centre, Birmingham, B15 2TH, UK.
Summary A pilot study was undertaken in eight patients to assess the feasibility of recombinant human
granulocyte-macrophage colony-stimulating factor (rH GM-CSF) support to intensify standard chemotherapy
for advanced ovarian cancer using a shortened 15 day treatment interval. Only four patients completed the
course of six cycles of cisplatin 75 mg m-2 and cyclophosphamide 750 mg m-2 with rH GM-CSF,
3-5 fig kg- day-', days 3-14, but one of these suffered a toxic death on study. Another died of disease
progression. There were two episodes of life-threatening infection (WHO grade 4), and three patients were
withdrawn because ofvarious rH GM-CSF-related problems. Although potentially affording some patients the
hypothetical benefits of dose intensification, as well as the possible attraction of a shorter duration of
chemotherapy, this regimen is not without problems.
Cisplatin combined with cyclophosphamide affords high re-
sponse rates in ovarian cancer (Neijt et al., 1987). Both
experimental and clinical studies have suggested a positive
correlation between cisplatin dose intensity and response
(Behrens et al., 1985; Levin & Hryniuk, 1986; Ngan et al.,
1989). This has recently been confirmed by a prospective
randomised trial (Kaye et al., 1992) which showed a survival
benefit for a delivered dose intensity of cisplatin of
29.6mg m2-week-' vs 16.3 mgm2 week-'. While the shape
of this dose-response curve remains uncertain, the further
reduction of toxicity in pursuit of higher delivered dose
intensity remains a major objective in the development of
more effective chemotherapy for epithelial ovarian cancer.
Attempts to exploit the differing dose-limiting toxicities of
cisplatin and carboplatin by their use in combination are, as
yet, inconclusive (Calvert, 1989; Lund et al., 1989; Muggia et
al., 1990; Poole et al., 1992). Bone marrow suppression re-
mains a major dose-limiting toxicity of any intensification
programme and, while transfusion may reduce the effects of
anaemia and thrombocytopenia, profound leucocyte nadirs
predispose to infection and cause treatment delay.
Recombinant human granulocyte-macrophage colony-
stimulating factor (rH GM-CSF) stimulates the growth and
differentiation ofmultiple lineages ofhaemopoietic cells (Sieff
et al., 1985; Metcalf et al., 1986) and increases peripheral
blood neutrophil, monocyte and eosinophil counts. It
therefore has the apparent potential to abrogate dose-limiting
myelosuppression and permit safe treatment intensification.
A reduction in the standard 21 day cycle interval for cisplatin
75 mgm2 and cyclophosphamide 750 mgm2 is one such
approach. The objective of this study was to establish the
feasibility of using rH GM-CSF support to achieve a 15 day
dose interval for six cycles of this combination.
Patients and methods
Eight patients were recruited to the study, and their charac-
teristics are shown in Table I. Entry criteria comprised histo-
logically confirmed epithelial ovarian carcinoma, age 18-70
years, ECOG performance status of <2, assessable residual
disease, a white cell count (WCC) > 3.5 x 1091-, platelet
count > 125 x 091-', serum bilirubin <1.5 times upper nor-
mal, AST/ALT< twice the upper normal value, creatinine
clearance >50 ml min-'. Ethical approval was obtained for
the study, and all patients gave written informed consent
prior to entry. Patients with a history of other malignancies,
previous exposure to chemotherapy and/or cytokines and
serious medial conditions were excluded. Response rates were
assessed by UICC criteria, including CA-125 level (UICC,
1987).
rH GM-CSF (Schering/Plough) was administered sub-
cutaneously, from day 3 to 14, at a dose of 3 ,g kg-' day-'.
The first two injections were supervised in hospital, in order
to detect known adverse reactions (Lieschke et al., 1989a).
Haematological and biochemical profiles were checked thrice
weekly for two cycles, and then weekly. The second cycle of
therapy was started on day 15. In the even of an unaccep-
tably low leucocyte or neutrophil count at the time of subse-
quent treatment, the dose of rH GM-CSF was increased to
5jig kg-' day-', and chemotherapy restarted when the WCC
rose above 3.0 x 10 1-' and platelets above 100 x1091- 1.
After the last cycle of chemotherapy, rH GM-CSF was con-
tinued for 15 days, or longer if required. In the event of the
WCC exceeding 30 x 10 l-' at any time, rH GM-CSF was
stopped.
Results
A total of 44 cycles of chemotherapy were administered, 35
(80%) in combination with rH GM-CSF. Four patients com-
pleted six cycles of treatment under rH GM-CSF cover.
Table I Patient characteristics
Number
Age 39-66 years (median 42 years)
Histology
Serous
Mucinous
Adenocarcinoma (unspecified)
Stage
III
IV
Differentiation
Moderate
Poor
Unknown
Residual tunour
<2cm maximum diameter
>2 cm maximum diameter
3
3
2
7
4
3
7
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Three patients were withdrawn from study and the indica-
tions were: (i) fever and night sweats after the third cycle,
resolving on cessation of rH GM-CSF; (ii) non-response to
rH GM-CSF, requiring withdrawal from study after the
second cycle; (iii) maculopapular rash and pruritus after the
third cycle.
Delays were recorded in nine (26%) cycles of chemo-
therapy. No delay exceeded 8 days in any individual cycle.
Causes included leucopenia/neutropenia (five cases), anaemia
and thrombocytopenia (two cases) and suspected infection
(two cases). Two patients required rH GM-CSF dose escala-
tion to 5fig kg-' day-' because of leucopenia.
Chemotherapy-associated toxicity is shown in Table II.
Five patients required admission for blood transfusion, and
one for platelet transfusion. Four patients had suspected
infection, and these were life-threatening in two. In addition
one patient died from resistant Staphylococcus aureus
pneumonia and septicaemia. This complicated neutropenia 8
days following the final cycle of treatment, and occurred
despite prompt medical attention and intensive care. One
patient developed cisplatin-induced nephrotoxicity after the
last cycle of therapy, with a reduction in creatinine clearance
to 35 ml min-'. Only one patient developed symptoms of a
mild sensory peripheral neuropathy.
Specific rH GM-CSF-related side-effects occurred in six
patients (Table III). Two patients had transient elevations of
alkaline phosphatase which returned to normal on cessation
of rH GM-CSF. Two patients complained of fever and night
sweats, and another two developed skin reactions at injection
sites. One patient had an allergic reaction. This developed
following the third course of therapy. The patient was admit-
ted with a pruritic maculopapular rash which responded
rapidly to intravenous Piriton and hydrocortisone. A WCC
above 20 x I09 I' was recorded on at least one occasion in
all patients with one episode of a level above 30 x I091'.
The effects on mean values of leucocytes, neutrophils and
eosinophils are shown in Figure 1.
Dose intensity achieved
The planned duration of treatment was 75 days for six cycles.
One patient died of disease progression immediately after her
third cycle (without treatment delays), and four patients com-
pleted treatment with growth factor support in a total of 75,
78, 90 or 98 days. The one patient who completed chemo-
therapy in 75 days died from sepsis on day 8 of cycle 6.
Records confirmed the duration of her previous nadirs at less
than 48 h. Of the three patients who were withdrawn from
rH GM-CSF, two received two cycles of therapy with rH
GM-CSF support, after delays of just 1 and 3 days each.
They subsequently completed chemotherapy in 91 days (five
cycles only) and 126 days respectively. The last patient was
on schedule when withdrawn immediately after her second
cycle, and thereafter finished treatment in 128 days. Using
the recommendations of Hryniuk and Goodyear (1990) we
calculate the received dose intensities as shown in Table
IV.
Response andsurvival
Six of the eight patients achieved complete clinical responses.
One of these (patient 2) was confirmed as a pathological CR
at autopsy following septic death. Two patients had non-
responsive disease, and one of these died during the study of
disease progression. To date four patients have died at 7, 11,
12 and 13 months from entry. Two other patients are alive at
20 and 26 months from entry, though both have evidence of
relapsed disease.
Table II Toxicity (WHO grade) (most severe toxicity noted in any
patient)
Grade 0 1 2 3 4
Peripheral neuropathy 7 0 1 0 0
Nausea/vomiting 0 2 3 2 1
Alopecia 0 3 4 1 0
Neutropenia 3 0 1 2 2
WCC 3 2 2 1 0
Sepsis 4 0 2 0 2
Platelets 6 1 0 1 0
Hb 1 1 5 1 0
Creatinine 7 0 1 0 0
Table III GM-CSF-related side-effects
Symptoms Number
Sweats/fevers 2a
Injection site reaction 2
Allergic type reaction 1
Skin rash I
Raised alkaline 2
phosphatase
aOne patient requested withdrawal from study.
Table IV Dose intensity achieved
Patient no. Cycles Cycles with Received intensity cisplatin
GM-CSF (mgm-2 week-')
1 3 3 36
2 6 6 35
3 6 6 34
4 6 6 30
5 6 6 28
6 5 2 23
7 6 2 21
8 6 1 21
Average dose intensity 28
Median dose intensity 28
Average dose intensity in patients 32
completing therapy with GM-CSF
n=8 n=4
C)
x
C-) _
n
1 2 3 4 5 6
Cycle number
Figure 1 Mean counts during therapy on
neutrophils; *, leucocytes; 0, eosinophils.
rH GM-CSF. A,
Discussion
This is the first report addressing the use of rH GM-CSF to
intensify cisplatin and cyclophosphamide chemotherapy in
ovarian cancer. Other studies have used rH GM-CSF sup-
port for carboplatin treatment of patients with ovarian
cancer (de Vries et al., 1991; Edmonson et al., 1992) and
comparisons must therefore be qualified. deVries et al. (1991)
undertook a randomised placebo-controlled trial and found a
reduction in the severity of both neutropenia and throm-GM-CSF AND CISPLATIN/CYCLOPHOSPHAMIDE IN OVARIAN CANCER 539
bocytopenia with the addition of rH GM-CSF (3-6,tg kg-'
day-' s.c.) to carboplatin 300 mg m2 and cyclophosphamide
750 mg m2 administered every 4 weeks. Edmonson et al.
(1992) employed various doses and routes of GM-CSF
administration with intensification of carboplatin/
cyclophosphamide. They concluded that the most efficacious
regimen was GM-CSF5 lAg kg-' s.c. every 12 h from days 6
to 3 prior to chemotherapy and days 1-14 with cyclophos-
phamide 1,000mgm2 and carboplatin 600mgm2 every 4
weeks. Tolerability problems encountered in both of these
series were similar to our study. deVries et al. (1991) reported
local skin reactions at injection sites in all patients, resulting
in the withdrawal of two patients. Another two patients
developed a generalised rash with itching following the first
or second cycle of treatment. In their study no fever or
hypotensive reactions were observed. Edmonson et al. (1992)
detected these, and with higher doses encountered the more
serious side-effects of pleuritis, pericarditis, atrial fibrillation
and pulmonary reactions. Two of three patients receiving
GM-CSF at 10gAg kg-' every 12 h on days 6 to 3 prechemo-
therapy and days 1-14 developed exfoliative dermatitis. This
regimen was abandoned because of such severe toxicity. In
Edmonson et al.'s series of 30 patients with 'ovarian car-
cinoma' only ten completed therapy as planned. One patient
was withdrawn because of GM-CSF-induced pulmonary
reaction, three because ofdisease progression and one patient
refused further treatment after the third completed cycle.
Five patients completed four or five cycles of treatment but
no indication is given as to why they had not completed a
full course as planned. Ten patients were withdrawn from
study, although it is not stated whether this was toxicity
related.
Myelosuppression is a major obstacle to dose intensifi-
cation of chemotherapeutic regimens. Maintenance of neut-
rophil count is important as severe infection in neutropenic
patients increases particularly at counts below 0.5 x i091-'
(Bodey et al., 1966). Severe (WHO grade 3/4) neutropenia
was encountered in three patients in this series, and one
patient (number 2) died of staphylococcal sepsis on day 8 of
her sixth cycle of treatment. Transient leucopenia was
expected after each dose of rH GM-CSF-covered chemo-
therapy (Devereux et al., 1987), but it had been hoped that
the risks of serious infection might be low, reflecting both the
short duration of the nadir and the relative rarity of concur-
rent oral mucositis with these drugs. It is notable that in
patient No. 2 recorded WCC nadirs had been of less than
48 h duration prior to her fatal sixth cycle.
Another striking event was the failure to obtain a WCC
increment in one patient. Unfortunately, no information is
available about the possible presence of neutralising
antibodies, although this is considered a rare phenomenon
(Gribben et al., 1990).
rH GM-CSF side-effects such as pyrexia and sweats (and
raised WCC) (Licschke et al., 1990) pose a diagnostic
dilemma for the physician, mimic sepsis, and often result in
patients' admission, investigation and empirical antibiotic
treatm&nt, and on occasion cause chemotherapy delay. In
this series two patients had delayed treatment because of
suspected infection, although no organism was identified on
routine investigations. One patient requested withdrawal
from the trial because of night sweats, after an increase in
dose to 5fig kg-' day-1. As has been reported elsewhere
(Lieschke et al., 1989b) two patients developed erythematous
local reactions at their injection sites.
rH GM-CSF has occasionally been reported to have a
beneficial effect on platelet production in both animal and
human studies. In mice, platelet recovery after irradiation
was enhanced by the introduction of GM-CSF (Tanikawa et
al., 1989), and two clinical series allude to higher platelet
counts and a reduction in platelet transfusion requirement
following rH GM-CSF (Gianni et al., 1990; Edmondson et
al., 1992). We did not detect any such effect. Only one
patient had increased platelet counts. We suspected this was
tumour induced, and related to disease progression. Haemo-
globin concentrations fell across treatment, with transfusions
necessary in five patients. As expected, marked eosinophilia
occurred in all patients, reflecting increased eosinophil prod-
uction and cellular half-life (Owen et al., 1987).
In such a small series response and survival rates merit
little comment, but no obvious adverse effects on tumour
growth were seen.
This preliminary series shows that rH GM-CSF can be
used to support intensification of combined cisplatin/
cyclophosphamide chemotherapy. The average dose intensity
achieved was 28 mg m-2week-', which falls short of the
intended 37.5 mgm-2 week-'. This compares favourably
though with previous studies from this group, which demon-
strated that for an intended dose intensity of 25mgm-'
week'l (cisplatin 75 mgm2 and cyclophosphamide
750 mg m-2 every 3 weeks), the actual average dose intensity
achieved was 20.3 mgm2week-'. It is therefore possible to
support intensification of delivered dose using rH GM-CSF.
However, the use of rH GM-CSF is not without problems.
In 3/8 patients rH GM-CSF was withdrawn because of fever
and night sweats, non-response to chemotherapy and the
development of an allergic skin reaction. rH GM-CSF in this
series did not entirely prevent serious infections, and there
were two episodes of life-threatening sepsis and one death
from Staph. aureus pneumonia and septicaemia.
Interestingly, some patients elected to persist with rH GM-
CSF despite troublesome local skin reactions, clearly
motivated by the prospect of a reduction in the overall
duration of their chemotherapy. This demonstrates the
importance of including a detailed quality-of-life assessment
in future studies. It seems plausible that higher doses of rH
GM-CSF may be required to condense cycle intervals fur-
ther, which presumably will increase the incidence of local
adverse reactions, fevers and sweats.
Because of the problems that we have encountered and the
small increase in average delivered dose intensity obtained,
we have no immediate plans to embark on further
intensification studies employing rH GM-CSF. Were we to
pursue this further the most informative setting might be a
randomised phase II study, against the same schedule sup-
ported by rH GM-CSF, incorporating quality-of-life end
points.
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